A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover
about
Matriptase-2, a membrane-bound mosaic serine proteinase predominantly expressed in human liver and showing degrading activity against extracellular matrix proteinsThe serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelinThe activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitorActivation of human meprin-alpha in a cell culture model of colorectal cancer is triggered by the plasminogen-activating systemProteomic-based detection of a protein cluster dysregulated during cardiovascular development identifies biomarkers of congenital heart defectsEvidence for the occurrence of membrane-type serine protease 1/matriptase on the basolateral sides of enterocytesRoles of functional and structural domains of hepatocyte growth factor activator inhibitor type 1 in the inhibition of matriptaseProtein interaction analysis of ST14 domains and their point and deletion mutants.Cleavage specificity analysis of six type II transmembrane serine proteases (TTSPs) using PICS with proteome-derived peptide librariesMatriptase is involved in ErbB-2-induced prostate cancer cell invasionTransport via the transcytotic pathway makes prostasin available as a substrate for matriptaseMechanisms of disease: protease functions in intestinal mucosal pathobiologyAntithrombin regulates matriptase activity involved in plasmin generation, syndecan shedding, and HGF activation in keratinocytes.HAI-2 suppresses the invasive growth and metastasis of prostate cancer through regulation of matriptase.Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract.Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding type II transmembrane serine protease matriptase.The molecular and clinical impact of hepatocyte growth factor, its receptor, activators, and inhibitors in wound healing.Membrane-anchored serine proteases in health and disease.Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas.Polarized epithelial cells secrete matriptase as a consequence of zymogen activation and HAI-1-mediated inhibition.A recombinant matriptase causes an increase in caspase-3 activity in a small-intestinal epithelial IEC-6 line cultured on fibronectin-coated plates.Impact of suppression of tumorigenicity 14 (ST14)/serine protease 14 (Prss14) expression analysis on the prognosis and management of estrogen receptor negative breast cancer.The role of type II transmembrane serine protease-mediated signaling in cancer.Overexpression of matriptase correlates with poor prognosis in esophageal squamous cell carcinoma.Regulation of pericellular proteolysis by hepatocyte growth factor activator inhibitor type 1 (HAI-1) in trophoblast cells.Matriptase does not require hepatocyte growth factor activator inhibitor type-1 for activation in an epithelial cell expression model.The occurrence of matriptase C-terminal fragments on the apical and basolateral sides of Madin-Darby canine kidney epithelial cells.Requirement of the activity of hepatocyte growth factor activator inhibitor type 1 for the extracellular appearance of a transmembrane serine protease matriptase in monkey kidney COS-1 cells.Autoactivation of matriptase in vitro: requirement for biomembrane and LDL receptor domain.Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis.Matriptase shedding is closely coupled with matriptase zymogen activation and requires de novo proteolytic cleavage likely involving its own activity.Involvement of the cytoplasmic juxtamembrane region of matriptase in its exclusive localization to the basolateral membrane domain of Madin-Darby canine kidney epithelial cells.Roles of CUB and LDL receptor class A domain repeats of a transmembrane serine protease matriptase in its zymogen activation.Alpha1-antitrypsin inhibits the activity of the matriptase catalytic domain in vitro.Identification of the matriptase second CUB domain as the secondary site for interaction with hepatocyte growth factor activator inhibitor type-1.Characterization of matriptase expression in normal human tissues.Autosomal ichthyosis with hypotrichosis syndrome displays low matriptase proteolytic activity and is phenocopied in ST14 hypomorphic mice.Intestinal regulation of suppression of tumorigenicity 14 (ST14) and serine peptidase inhibitor, Kunitz type -1 (SPINT1) by transcription factor CDX2
P2860
Q24302437-6AD5E208-B9C3-41FD-B4BC-F4FA53FD2A57Q28115763-1365B857-F3BE-4AB6-80F5-340CA3FBA186Q28203364-C970DA9A-F35A-46FD-8CC5-94873148F406Q28218647-29EC9D1B-205D-4B27-80C6-EC94AD273368Q28509745-12072082-60BB-4A91-8A1B-990E79BD7FF8Q28564911-E984B19C-D1D6-4A36-9AE4-42492CF1910BQ28572367-916E74CD-7BBD-4189-8E3D-0CCA1824BB50Q33231437-699C485B-FEB2-453F-88B2-BC1E1D425BC4Q34165943-0CEF0567-140D-4C09-9BA0-CB6735214AFDQ34358331-45846010-3D4B-4F43-940E-5416EA4ADB68Q34568634-14B043A2-57E0-4429-87D0-6EACC9393806Q34626040-AAD29754-C93B-4A47-BAAF-8E88CA6F6789Q34722698-E54690E0-8663-4B87-B734-EB7D34333A35Q35041020-50AB5AB2-D2EB-4A93-985F-62EAF1C33CFBQ35621356-4E23609A-F84B-4F98-80ED-EF7DD75EB547Q35677751-D65B9E1B-E383-4C3F-9608-9DDDD862BA4BQ36395707-990C8B65-4C97-4084-88EE-F8917C339081Q36969010-C560C4F9-EA11-4273-AC53-609887E1B439Q37218234-2C3E3937-1A6C-4DC1-9DF5-837CD8645013Q37298015-EB7F5F63-1B17-4456-A522-45395A70C64CQ38598028-97DBA453-8F8D-4B27-B6BA-25C8B0094E52Q38771773-90C2C746-A959-4E95-A03B-F5A2A2DA0F59Q39015415-C3F36C7F-5E8D-4B02-9023-C777538D84DCQ39061621-CB2E3D44-FB3D-4BA7-BE96-F574F0F95EC5Q39224627-10DB4CD2-EBEA-4813-91DA-268F241C0AF7Q39716974-F94DE1FC-249B-4C0C-9D88-50EA2909A764Q39777502-0DA56B83-79C0-40C6-9B3B-B9D21309B861Q39816749-9143E198-0480-4667-8D5D-CF0CEB6ACB46Q40161979-72D982B9-6384-4D34-AFE9-1E824B1AA5BCQ40227949-E9E46C0F-C0BB-42E0-B825-A135BCD1B546Q41492870-1065A77C-9262-469E-AD55-599C302FC1E8Q41838674-B984DC71-CCEF-46B9-8215-BE3900AB6050Q41889043-6FB2E2E9-2461-469B-9789-E290F86FF4C2Q42116993-8DADC0CC-CB01-424A-96D2-5C2867879250Q42399102-EE7CC392-E98B-4EEB-945A-29725917FD41Q44519409-BA2894A4-FA4D-4C7E-AB83-943DE414D443Q46947626-D9999015-CDFA-49E0-BD27-75B2750BA721Q58797861-91116A31-8A8A-43C2-A353-E529F814BF41
P2860
A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover
description
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2001
@ast
im Oktober 2001 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2001/10/05)
@sk
vědecký článek publikovaný v roce 2001
@cs
wetenschappelijk artikel (gepubliceerd op 2001/10/05)
@nl
наукова стаття, опублікована в жовтні 2001
@uk
مقالة علمية (نشرت في 5-10-2001)
@ar
name
A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover
@ast
A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover
@en
A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover
@nl
type
label
A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover
@ast
A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover
@en
A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover
@nl
prefLabel
A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover
@ast
A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover
@en
A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover
@nl
P2093
P3181
P356
P1476
A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover
@en
P2093
S. Tsuzuki
T. Fushiki
T. Iwanaga
Y. Yamasaki
P304
P3181
P356
10.1006/BBRC.2001.5686
P407
P577
2001-10-05T00:00:00Z